Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Studies heart rhythm changes in people taking BTK inhibitors or venetoclax

Observes heart rhythm effects in adults with blood cancers taking BTK inhibitors or venetoclax.

Plain-language title generated from the registry record
Registry title: Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Key facts

Where
Bethesda, United StatesSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 110 years old?

Source: NCT05724121, who can take part

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Heart, Lung, and Blood Institute (NHLBI)
Trial code
NCT05724121
Record updated
29 October 2026
Original description
Background:Read full original descriptionShow less

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Background:

Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart.

Objective:

To identify and monitor the effects of BTKi on the heart.

Eligibility:

People aged 18 and older currently receiving or planning to receive BTKi or venetoclax.

Design:

Participants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit.

Participants will undergo multiple tests:

A physical exam, including collection of blood and saliva.

A test that measures heart activity via stickers placed on the chest.

A test that uses sound waves to capture images of the heart.

An exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises.

Stress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken.

Participants may wear a device to monitor their heart at home.

Participants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years.

Exclusion: Pregnancy or lactation- use of BTK inhibitors is contraindicated in pregnant or nursing individuals; Any acute cardiac condition including myocardial infarction or decompensated heart failure within the past 3 months; An individual who meets any of the following criteria will be excluded from participation in this study:.

INCLUSION CRITERIA:; To be eligible to participate in this study, an individual must meet all of the following criteria:; Currently receiving or planning to receive a BTKi or venetoclax; Male or female, aged 18 or older; Stated willingness to comply with all study procedures and availability for the duration of the study; Ability of subject to understand and the willingness to sign a written informed consent document.

ClinicalTrials.gov NCT05724121